Veracyte, Inc. (VCYT)
NASDAQ: VCYT · IEX Real-Time Price · USD
23.18
-0.75 (-3.13%)
At close: Jul 19, 2024, 4:00 PM
23.58
+0.40 (1.73%)
Pre-market: Jul 22, 2024, 6:00 AM EDT
Veracyte Revenue
Veracyte had revenue of $375.47M in the twelve months ending March 31, 2024, with 20.66% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $96.84M with 17.50% year-over-year growth. In the year 2023, Veracyte had annual revenue of $361.05M with 21.76% growth.
Revenue (ttm)
$375.47M
Revenue Growth
+20.66%
P/S Ratio
4.72
Revenue / Employee
$460,703
Employees
815
Market Cap
1.77B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 361.05M | 64.52M | 21.76% |
Dec 31, 2022 | 296.54M | 77.02M | 35.09% |
Dec 31, 2021 | 219.51M | 102.03M | 86.85% |
Dec 31, 2020 | 117.48M | -2.89M | -2.40% |
Dec 31, 2019 | 120.37M | 28.36M | 30.82% |
Dec 31, 2018 | 92.01M | 20.06M | 27.87% |
Dec 31, 2017 | 71.95M | 6.87M | 10.55% |
Dec 31, 2016 | 65.09M | 15.58M | 31.48% |
Dec 31, 2015 | 49.50M | 11.31M | 29.62% |
Dec 31, 2014 | 38.19M | 16.31M | 74.51% |
Dec 31, 2013 | 21.88M | 10.26M | 88.20% |
Dec 31, 2012 | 11.63M | 8.98M | 339.62% |
Dec 31, 2011 | 2.65M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Harmony Biosciences Holdings | 617.51M |
Zai Lab | 291.07M |
Ligand Pharmaceuticals | 118.31M |
RxSight | 101.10M |
Keros Therapeutics | 234.00K |
VCYT News
- 4 days ago - Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024 - Business Wire
- 6 weeks ago - Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors - Business Wire
- 2 months ago - Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer - Business Wire
- 2 months ago - Veracyte to Participate in Upcoming Investor Conferences - Business Wire
- 2 months ago - Veracyte Announces First Quarter 2024 Financial Results - Business Wire
- 2 months ago - 14 Studies Presented at AUA 2024 Show Decipher Tests' Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding - Business Wire
- 3 months ago - Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024 - Business Wire
- 3 months ago - New Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance - Business Wire